Novartis Vaccines, Siena, Italy.
Novartis Vaccines, Siena, Italy.
Curr Opin Microbiol. 2015 Feb;23:68-72. doi: 10.1016/j.mib.2014.11.006. Epub 2014 Nov 22.
The recent advances in cellular microbiology, genomics, and immunology has opened new horizons in the understanding of meningococcal pathogenesis and in the definition of new prophylactic intervention. It is now clear that Neissera meningitidis has evolved a number of surface structures to mediate interaction with host cells and a number of mechanisms to subvert the immune system and escape complement-mediated killing. In this review we report the more recent findings on meningococcal adhesion and on the bacteria-complement interaction highlighting the redundancy of these mechanisms. An effective vaccine against meningococcus B, based on multiple antigens with different function, has been recently licensed. The antibodies induced by the 4CMenB vaccine could mediate bacterial killing by activating directly the classical complement pathway or, indirectly, by preventing binding of fH on the bacterial surface and interfering with colonization.
细胞微生物学、基因组学和免疫学的最新进展为我们理解脑膜炎奈瑟菌的发病机制和确定新的预防干预措施开辟了新的视野。现在很清楚，脑膜炎奈瑟菌已经进化出许多表面结构来介导与宿主细胞的相互作用，以及许多机制来颠覆免疫系统并逃避补体介导的杀伤。在这篇综述中，我们报告了关于脑膜炎奈瑟菌黏附和细菌-补体相互作用的最新发现，强调了这些机制的冗余性。最近，一种基于多种具有不同功能抗原的针对脑膜炎球菌 B 的有效疫苗已经获得许可。4CMenB 疫苗诱导的抗体可以通过直接激活经典补体途径或通过阻止 fH 在细菌表面的结合和干扰定植来间接介导细菌杀伤。
